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Solid tumors develop as 3D tissue constructs. As tumors grow larger, spatial 
gradients of nutrients and oxygen and inadequate diffusive supply to cells 
distant from vasculature develops. Hypoxia initiates signaling and tran-
scriptional alterations to promote survival of cancer cells and generation of 
cancer stem cells (CSCs) that have self-renewal and tumor-initiation capabili-
ties. Both hypoxia and CSCs are associated with resistance to therapies and 
tumor relapse. This study demonstrates that 3D cancer cell models, known 
as tumor spheroids, generated with a polymeric aqueous two-phase system 
(ATPS) technology capture these important biological processes. Similar to 
solid tumors, spheroids of triple negative breast cancer cells deposit major 
extracellular matrix proteins. The molecular analysis establishes presence 
of hypoxic cells in the core region and expression of CSC gene and protein 
markers including CD24, CD133, and Nanog. Importantly, these sphe-
roids resist treatment with chemotherapy drugs. A combination treatment 
approach using a hypoxia-activated prodrug, TH-302, and a chemotherapy 
drug, doxorubicin, successfully targets drug resistant spheroids. This study 
demonstrates that ATPS spheroids recapitulate important biological and 
functional properties of solid tumors and provide a unique model for studies 
in cancer research.
subunits and their translocation to the 
nucleus. Binding of HIF transcription 
factors to hypoxia-responsive elements 
in target genes leads to activation of hun-
dreds of genes that enable cells to adapt 
to low oxygen and survive in hypoxic envi-
ronments.[4] Hypoxia promotes resistance 
to chemotherapy and radiation therapy 
through mechanisms such as altered cel-
lular metabolism and genetic instability 
that drive formation of drug resistant sub-
populations of cells.[5] More recent studies 
show that tumors often harbor cells with 
self-renewal and drug resistance capabili-
ties, i.e., cancer stem cells (CSCs).[6,7] It 
is known that HIF-1 expression induces 
expression of genes, such as a gene 
encoding the stem cell factor that partici-
pate in stem cell maintenance.[8,9] Tumor 
hypoxia and presence of CSCs correlate 
with chemotherapy resistance, which is 
a main reason for failure of cancer treat-
ment in patients with advanced, inoper-
able cancers.[10]
Widely used monolayer (2D) cell 
cultures permit cancer cells unrestricted 
access to nutrients and oxygen, unlike solid tumors. As a result, 
critical elements such as mechanical and biochemical signaling 
and intercellular communications present in tumors are absent 
from standard 2D cell cultures.[11,12] To study solid tumors in 
vitro, it is essential to employ culture systems that preserve 
their biological properties. 3D cultures provide a unique tool to 
model tumor environments.[13] Cancer cell spheroids present a 
relevant model due to their 3D structure, complex intercellular 
network, and restricted diffusion of nutrients and oxygen.[14,15] 
Unfortunately, spheroid culture techniques face difficulties 
in production of consistently-sized spheroids in standard lab-
ware, ease of maintenance, drug treatment, analysis of cellular 
responses, and downstream molecular analysis. To facilitate 
routine use of spheroids, we have developed a high throughput 
spheroid printing microtechnology using a polymeric aqueous 
two-phase system (ATPS) that allows simple and quick spheroid 
formation in standard microwell plates. Here, we utilize triple 
negative breast cancer (TNBC) as a model for biological and 
functional characterization and drug response analysis of ATPS 
spheroids. TNBC is the most lethal subtype of breast cancer. 
Treatment options for TNBC are limited, underscoring the need 
for new approaches to therapy.[16]
To generate spheroids with ATPS technology, a submicro-
liter drop of the denser polymeric aqueous phase mixed with 
1. Introduction
During early stages of epithelial cancers, neoplastic cells invade 
through the basement membrane and proliferate abnormally 
as 3D cellular masses supplied with nutrients through simple 
diffusion from surrounding vasculature.[1,2] The resulting 
solid tumors contain phenotypically and functionally hetero-
geneous cells and continue to grow until availability of oxygen 
and nutrients to cells distant from surrounding vasculature 
becomes limited.[1–3] Tumor hypoxia activates hypoxia-inducible 
factor (HIF) pathway by promoting protein stability of HIF-α 
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cancer cells is robotically dispensed into 
wells of a nonadherent microwell plate con-
taining the immersion polymeric aqueous 
phase. The drop phase maintains cancer 
cells in close proximity and facilitates forma-
tion of a single spheroid upon incubation. 
The ATPS technology is adapted to standard 
384 microwell plates where spheroids can 
easily be maintained or treated by direct 
addition of media or drug solutions, respec-
tively. Additionally, drug responses can be 
conveniently evaluated using standard plate 
readers by direct addition of cellular viability 
reagents. We demonstrate that TNBC sphe-
roids formed with the ATPS technology 
reproduce key biological properties and func-
tionality of solid tumors including prolifera-
tion patterns, deposition of matrix proteins, 
hypoxia, expression of CSC markers, and 
drug resistance. Recapitulating these prop-
erties of tumors in vitro, coupled with the 
potential to incorporate other complexities of 
tumor microenvironment, makes the ATPS 
spheroid technology a unique 3D culture 
approach for generation of physiologically 
relevant tumor models for use in biological 
and drug screening studies.
2. Results and Discussion
2.1. ATPS Microprinting of Spheroids in 384 
Microwell Plates
The ATPS spheroid technology forms a single MDA-MB-157 
TNBC cell spheroid in each well of a standard 384 microwell 
plate within 24 h of incubation (Figure 1a). The key to this 
efficient process is the immiscibility of a 0.3 μL aqueous dex-
tran (DEX) phase drop and the immersion polyethylene glycol 
(PEG) phase and favorable partition of cells to the drop phase 
due to an ultralow interfacial tension between the two aqueous 
phases.[17–19] Use of two highly aqueous phases ensures free dif-
fusion of nutrients from the immersion phase to cells in the 
low-volume drop and removal of waste products of cells from 
the drop phase. Cancer cells restricted to the DEX phase drop 
spontaneously aggregate and form a spheroid. Printing MDA-
MB-157 spheroids with a density of 1.5 × 104 cells results in an 
average diameter of 235 μm with a standard deviation of ≈8% 
from the mean within each microplate (Figure 1b) that is repro-
ducible across different plates. The variation of dia meter for indi-
vidual spheroids is typical of a normal distribution (Figure 1b, 
inset). The ATPS approach reproducibly generates consistently-
sized spheroids at different cell densities (2.5 × 104, 5.0 × 104, 
and 1.0 × 105 shown in Figure SI-1 in the Supporting Informa-
tion). While this technique is compatible with manual pipet-
ting, the use of liquid handling robotics reduces variability and 
labor and increases precision and efficiency of dispensing low-
volume DEX phase drops into the aqueous PEG phase. Sphe-
roid consistency and uniformity upon formation are critical to 
establish a similar metabolic activity baseline for all spheroids in 
a microplate and ensure that differences in metabolic activity are 
caused by treatment with drug compounds and not variations in 
size of spheroids. Once spheroids form, they are conveniently 
maintained by direct addition of fresh media to the wells. The 
addition reduces concentrations of polymers below minimum 
concentrations required for maintaining a two-phase system 
and converts the ATPS to a single media phase. Therefore, ATPS 
is solely used as a patterning medium to generate spheroids. 
Micropatterning with ATPS has additionally facilitated the gen-
eration of cancer cell niches for migration studies.[20,21]
2.2. Evaluation of Cell Viability of Spheroids
We used a standard PrestoBlue assay to quantify viability of 
ATPS spheroids since it is a one-step addition assay that eradi-
cates the need for multiple wash steps or transfer of spheroids 
to special plates for viability analysis. PrestoBlue primarily has 
been used with 2D cultures, producing viability data similar to 
the conventional XTT (sodium 3′-[1-(phenyl amino-carbonyl)-
3,4-tetrazolium]-bis-[4-methoxy-6-nitro] benzene sulfonic acid 
hydrate) assay.[22] Spheroids of four different cell densities 
(1.5 × 104, 2.5 × 104, 5.0 × 104, and 1.0 × 105) were formed in a 
384 well plate and incubated with PrestoBlue. The media fluo-
rescent intensity due to the reduction of resazurin to resorufin 
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Figure 1. a) Spontaneous spheroid formation using aqueous two phase system (ATPS) micro-
technology; a compact MDA-MB-157 spheroid forms within 24 h of incubation (right). b) This 
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by metabolically active cells was measured for all four sphe-
roid densities every hour for 4 h (Figure 2). Between incuba-
tion time points of 2 and 3 h, the fluorescent signal became 
significantly different within each group, i.e., spheroids of the 
same cell density. With longer incubation time, the fluores-
cent signal differences became more pronounced. Based on 
a statistical analysis, it was validated that 3–4 h of incubation 
was optimal to measure cell viability of spheroids. Slower dif-
fusion of the resazurin component into spheroids is most 
likely the reason for the longer incubation time compared to 
2D cultures. Incubations longer than 4 h resulted in insignifi-
cant changes of the fluorescent signal within each group due 
to saturation. Thus, this test provided an optimal incubation 
time to evaluate cell viability of drug treated spheroids below. 
Our previous work also validated that the use of PrestoBlue 
allows us to sensitively detect increases in the fluorescent 
signal intensity from growing spheroids during long-term 
cultures.[23]
2.3. Extracellular Matrix Deposition of Spheroids
Cryosections of MDA-MB-157 spheroids were stained with 
hematoxylin and eosin (H&E) to examine their interior mor-
phology. This staining showed a highly compact and dense 
cellular network without any gaps (Figure 3a), similar to a pre-
vious study that reports TNBC patient tumors to be highly cel-
lularized and compact with a low fraction of extravascular and 
extracellular space.[24] Next, cryosections were immunostained 
for extracellular matrix (ECM) proteins type I collagen, laminin, 
and fibronectin. MDA-MB-157 spheroids of smaller cell den-
sity (1.5 × 104) showed expression of all three proteins, with 
greater abundance of collagen I and laminin (Figure 3b–d). 
Cell–ECM interactions play major roles in the tumor microenvi-
ronment.[25] Studies show that expression of both collagen I and 
fibronectin is elevated in breast cancer and associated with the 
tumor formation process.[25,26] Laminin is also highly expressed 
in invasive breast cancers and promotes cell migration, a pro-
cess fundamental to metastasis.[26] The expression of ECM pro-
teins is implicated in drug and radiation resistance of breast 
cancer cells.[26,27] Therefore, ATPS spheroids display critical 
cell–matrix interactions. Interestingly, larger density spheroids 
of MDA-MB-157 cells (1.0 × 105) showed lower expression of 
ECM proteins in the inner core cancer cells (Figure SI-2, Sup-
porting Information), suggesting reduced activity of these cells 
due to limited nutrients and oxygen.
2.4. Spheroid Size Dependent Proliferation and Hypoxia
We immunostained cryosections of MDA-MB-157 spheroids 
formed with 1.5 × 104 and 1.0 × 105 cells for the cell prolifera-
tion marker Ki-67. This staining showed differential distribu-
tion of proliferative cells. In smaller spheroids, proliferative 
cells were distributed homogenously throughout the spheroid 
(Figure 4a). By comparison, proliferative cells in larger sphe-
roids were mainly present toward the periphery of the spheroid 
(Figure 4b). Quantitative analysis of distribution of Ki-67+ cells 
confirmed this observation (Figure 4). Considering the average 
radius of large spheroids (220 ± 22 μm), it is likely that diffu-
sion limitations of nutrients and oxygen to cells residing in 
the core zone retards their proliferative activities. This is con-
sistent with suggested free diffusion distance of 150–200 μm.[28] 
Smaller sized spheroids with a radius of 118 ± 11 μm allow free 
diffusive molecular transport to support cellular proliferation in 
the central zone. Another potential cause for the lack of Ki-67+ 
cells in the core region of large spheroids is greater consump-
tion of nutrients and oxygen by densely packed cells at the 
Adv. Healthcare Mater. 2016, 5, 2788–2798
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Figure 2. Optimization of PrestoBlue assay to determine viability of cells 
in spheroid cultures. PrestoBlue is directly added to wells containing 
spheroids and metabolized by live cells. Based on the cellular metabolic 
activity, the solution emits a fluorescence signal detectable with standard 
plate readers. Incubation of spheroids with PrestoBlue for 3–4 h optimally 
resolves cell viability.
Figure 3. a) H&E staining of a 1.5 × 104 cell density MDA-MB-157 
spheroid shows a compact intercellular network. Blue and purple rep-
resent nuclei and cytoplasm, respectively. Immunohistochemical anal-
ysis for ECM proteins (shown in red) show deposition of b) collagen I, 
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peripheral zone. Unlike several other cancer cells we have used, 
MDA-MB-157 cells are tightly packed within spheroids, evident 
from the H&E staining result (Figure 3a). Therefore, in addition 
to limited diffusive transport, close intercellular contacts and 
packing of cancer cells within spheroids and consumption of 
available oxygen and nutrients by cells in peripheral layers is a 
potential cause of lack of proliferative activity in the core region. 
Assuming a spherical shape for spheroids, 85% of cells in the 
large spheroids reside in a spherical shell defined by the radii 
of 1.5 × 104 and 1.0 × 105 cell spheroids, supporting the above 
explanation. Nonuniform distribution of proliferative cells is 
reminiscent of solid tumors with poor vascularization.[29]
The disparity between oxygen demand and consumption of 
cancer cells in solid tumors generates hypoxia.[30] Tumor hypoxia 
has been implicated in processes including cancer cell survival, 
resistance to cell death, tumor angiogenesis, invasion, metastasis, 
radioresistance, and chemoresistance. Hypoxic regions occur 
more commonly in TNBC than other molecular subtypes of 
this disease.[28,31–33] Therefore, we investigated whether hypoxia 
could account for lack of cell proliferation in the core of the large 
TNBC spheroids. We used an exogenous 2-nitroimidazole probe, 
pimonidazole, that binds covalently to SH-containing molecules 
(thiols) in hypoxic tissues with less than 10 mmHg of oxygen 
partial pressure.[28,33] Cryosections of large TNBC spheroids 
stained positive in their core region (Figure 5a), whereas smaller 
spheroids lacked pimonidazole staining (Figure 5b). We further 
validated this result by measuring an endogenous transcriptional 
target of hypoxia-inducible factor-1 (HIF-1), carbonic anhydrase 
IX (CA IX). CA IX is a surrogate hypoxia marker, regulator of pH 
of the tumor microenvironment, and a prognostic factor found 
significantly more in basal-like breast tumors.[34,35] Our q-PCR 
analysis showed that large TNBC spheroids display a 39.2-fold 
Adv. Healthcare Mater. 2016, 5, 2788–2798
www.advhealthmat.de
www.MaterialsViews.com
Figure 4. Immunostained cryosections of a) 1.5 × 104 and b) 1.0 × 105 cell density spheroids show the distribution of Ki-67 positive (pink) prolifera-
tive cells. Analysis of stained sections is used to compare the distribution of nuclei (blue) and proliferative cells throughout each section. The larger 
spheroid contains a nonuniform distribution of proliferative cells compared to the smaller spheroid.
Figure 5. Pimonidazole staining (pink) of cryosections of a) 1.0 × 105 and b) 1.5 × 104 cell density spheroids of MDA-MB-157 shows presence of a 
hypoxic core only in the larger spheroid. c) q-PCR analysis of expression of the hypoxic marker CA IX in cells of both spheroids validates the results of 
immunostaining. mRNA levels are normalized with respect to a monolayer of MDA-MB-157 cells. Error bars represent the standard error of mean for 
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change in CA IX gene expression compared to smaller spheroids 
with only a 3.6-fold change (Figure 5c). These results are con-
sistent with cell proliferation patterns based on Ki-67 staining 
and explain the lack of proliferative activity. Considering slow 
cycling cells and activity of pro-survival pathways under hypoxic 
conditions,[36] the use of ATPS spheroids provides an opportu-
nity to study hypoxia-mediated drug responses of cancer cells 
with a biologically relevant tumor model and without inducing 
systemic atmospheric oxygen deficiency in culture which is the 
current standard to generate hypoxia.
2.5. Drug Resistance of Hypoxic Spheroids
MDA-MB-157 spheroids of both 1.5 × 104 and 1.0 × 105 cell den-
sities were treated with varying concentrations of doxorubicin, a 
standard chemotherapeutic drug currently used for TNBC treat-
ment (Figure 6a).[37] Spheroids showed a sigmoidal response to 
doxorubicin treatment; however, the larger spheroids displayed 
drug resistance. With a tenfold higher IC50 (481 × 10−9 m), the 
resulting cell viability of larger spheroids was much higher. The 
largest difference was a percent viability of 42% that occurred 
at a drug concentration of 100 × 10−9 m. Doxorubicin resistance 
of larger spheroids persisted at higher concentrations. First, we 
utilized the natural red fluorescence of doxorubicin to evaluate 
whether insufficient penetration of the drug into spheroids 
caused the observed resistance.[29] Fluorescent imaging of 
spheroids after 48 h of incubation with doxorubicin revealed a 
homogenous drug distribution within spheroids of both densi-
ties and a similar maximum signal intensity (Figure 6b,c) and 
presence of doxorubicin in the nuclei of cells (Figure 6d). This 
indicated that drug resistance of larger spheroids was not due 
to limited drug penetration.
Next, we asked whether hypoxia in larger spheroids mediates 
drug resistance. Hypoxic cells may show resistance to anticancer 
drugs for several reasons, including reduced proliferation and 
metabolism due to insufficient oxygen and nutrients, lost sen-
sitivity to p53-mediated apoptosis and consequent reduced 
sensitivity to certain drugs, and activation of genes involved 
in drug resistance including multidrug resistance 1 gene that 
encodes P-glycoprotein, acting as an efflux pump to reduce 
intracellular concentrations of some drugs.[10,28,33,38–43] We used 
a hypoxia activated prodrug, TH-302, that has progressed to 
clinical studies.[44] TH-302 is reduced under hypoxic conditions, 
Adv. Healthcare Mater. 2016, 5, 2788–2798
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Figure 6. a) Dose–response of 1.5 × 104 and 1.0 × 105 cell density MDA-MB-157 spheroids to doxorubicin treatment shows drug resistance of larger 
spheroids. Error bars represent the standard error of mean. b,c) Gray values of fluorescence intensity measurements along a sample line crossing 
spheroids of both densities show penetration of doxorubicin into spheroids after 48 h of incubation. d) Doxorubicin localization in the nuclei of 1.0 × 105 
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releasing a DNA crosslinker bromo-isophosphoramide mus-
tard.[45] This mechanism of TH-302 allows selective drug activa-
tion in hypoxic cells in a tumor and has shown hypoxia-induced 
cytotoxicity against 32 human cancer cell lines.[44] Larger sphe-
roids were co-treated with doxorubicin and TH-302 over wide 
range of concentrations for each compound. We note that 
only the larger (hypoxic) spheroids were co-treated due to the 
hypoxia-dependent mechanism of TH-302. Consistent with pre-
vious studies, TH-302 alone at the concentrations used was inef-
fective.[44,46] However, a major reduction in drug resistance was 
observed at 100 × 10−9 m doxorubicin with increasing TH-302 
concentration (Figure 7), suggesting that these compounds 
synergistically target cancer cells. The greatest effect was ≈30% 
reduced cell viability with combination treatment, i.e., 70.4% 
viability at 10 × 10−6 m TH-302/100 × 10−9 m doxorubicin com-
pared to 99.9% viability with 100 × 10−9 m doxorubicin treat-
ment alone, at which the largest drug resistance was observed 
(see Figure 6). The 10 × 10−6 m TH-302/100 × 10−9 m doxoru-
bicin combination of compounds was synergistic since the 
viability of co-treated larger spheroids (70.4%) was much lower 
than the viability data from treatment with each single com-
pound (91.6% at 10 × 10−6 m TH-302 and 99.9% at 100 × 10−9 m 
doxorubicin). We further validated synergism between the two 
compounds by calculating a combination index (CI), which is 
a quantitative measure where values smaller than unity indi-
cate synergism, using CompuSyn software.[47] The 10 × 10−6 m 
TH-302/100 × 10−9 m doxorubicin pair resulted in a CI value of 
0.02, demonstrating highly synergistic effects of the two drugs.
This screening approach allows identifying an optimal pair 
of concentrations of the cytotoxic compound to target prolifer-
ating cells and hypoxia-activated drug to target hypoxic cells. A 
similar result was found with a combination of a chemopreven-
tive agent (silibinin) and doxorubicin in which specific drug 
concentrations of 100 × 10−6 m silibinin/25 × 10−9 m doxoru-
bicin produced a synergistic effect in breast cancer cells.[48] Our 
result is also consistent with a few other studies, including a 
phase II clinical trial, that demonstrated synergistic effects of 
TH-302 combined with chemotherapy and radiotherapy treat-
ments against cancer cells.[45,49–51] The enhanced efficacy of 
doxorubicin at a low concentration of 100 × 10−9 m by addi-
tion of 10 × 10−6 m TH-302 is also advantageous from a prac-
tical standpoint to prevent/reduce cardiotoxic side effects.[52,53] 
Therefore, ATPS spheroids offer solid tumor models to identify 
effective drug combinations that reduce/overcome cancer cell 
resistance to chemotherapeutics.
We note that the combination of TH-302 and doxorubicin 
did not drop cell viability to that of 1.5 × 104 cell density sphe-
roids, i.e., 52.2%, at 100 × 10−9 m doxorubicin (diamonds in 
Figure 6a). This is potentially from the limited potency of the 
TH-302 compound and the involvement of additional mecha-
nisms of resistance, such as the inoculum effect, which causes 
reduced cytotoxic activity of a chemotherapy drug as the cancer 
cell density increases.[54] The inoculum effect with doxoru-
bicin results from insufficient number of drug molecules at 
high cell densities, causing a decreased drug accumulation in 
cancer cells.[54,55] For example, increasing the density of cancer 
cells resulted in a 27-fold decrease in the LD50 of doxorubicin 
against lymphoma cells[56] and 40 times lower growth-inhib-
itory capabilities (when comparing LD50 values) in leukemia 
cells.[55] Increasing doxorubicin concentrations substantially 
reduced this effect.[54] Our results also show that combination 
of 10 × 10−6 m TH-302 and 50 × 10−6 m doxorubicin reduces 
the cell viability to 45.9%, i.e., ≈26% further decrease compared 
to the 10 × 10−6 m TH-302/100 × 10−9 m doxorubicin pair and 
suggesting that the inoculum effect plays a role in doxorubicin 
resistance of MDA-MB-157 spheroids. Nevertheless, this cell 
viability is still greater than that of the 1.5 × 104 cell density 
spheroids at a similar doxorubicin concentration (see Figure 6), 
indicating that doxorubicin resistance is caused, at least in part, 
by hypoxia.
Previous studies showed that unlike with doxorubicin, the 
inoculum effect was not observed with cisplatin at various cell 
densities.[55,56] Therefore, we treated small and large spheroids 
of MDA-MB-157 cells with varying concentrations of cisplatin 
and determined cellular viability. Large spheroids still displayed 
resistance at effective concentrations of the drug and displayed 
≈35% greater viability than the small spheroids (Figure 8). Col-
lectively, our results indicate that the hypoxia in large sphe-
roids has a major influence on drug resistance of breast cancer 
cells in the absence of the inoculum effect, and that other 
phenomena such as the inoculum effect with certain chemo-
therapeutics and limited potency of TH-302 contribute to the 
observed doxorubicin resistance. A detailed study is required to 
distinguish between such effects.
2.6. Cancer Stem Cell Markers in Hypoxic Spheroids
Hypoxia in solid tumors is associated with stem cell-like 
cancer cells with tumor initiation, recurrence, and metastasis 
capacity.[57–62] It has been shown that hypoxic environments 
house stem cells because of their preference for low oxidative 
DNA damage,[57] and that CSCs rely on hypoxia induced fac-
tors for survival and self-renewal.[58] Chemotherapies typically 
kill the majority of cancer cells in tumors, but CSCs are able 
to evade therapy due to their resistance mechanisms.[63] The 
Adv. Healthcare Mater. 2016, 5, 2788–2798
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Figure 7. Surface plot of viability of 1.0 × 105 cell density spheroids of 
MDA-MB-157 cells co-treated with varying concentrations of doxorubicin 
and TH-302 shows synergistic enhancement in toxicity due to combina-
tion treatment. Color bar represents the cell viability range. Green and 
yellow squares represent cell viability of spheroids from treatment with 
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consequent survival of self-renewing CSCs causes recurrence of 
cancer.[63] To evaluate whether hypoxic tumor spheroids present 
stem cell markers and the utility of ATPS spheroids to study 
CSCs, we performed a gene expression study of breast CSC 
markers CD24, CD44, CD133 (prominin-1), ALDH1, and α6-
integrin, and pluripotency markers Oct4, Sox2, and Nanog.[64] 
This analysis was done in parallel with 1.5 × 104 and 1.0 × 105 
cell density spheroids of MDA-MB-157 cells, and resulting 
mRNA levels were normalized to that of a normoxic monolayer 
of cells for each gene marker. Among these markers, CD24, 
CD133, and Nanog showed greater expression in hypoxic, 
1.0 × 105 cell density spheroids (Figure 9a–c). Other markers 
either showed similar expression in both spheroids or lower 
expression than the monolayer of cells (Figure SI-3, Supporting 
Information). Increased expression of CD24 and CD133 in 
hypoxic spheroids was additionally confirmed at the protein 
level using immunostained cryosections (Figure 9d,e). Thus, 
our data suggests an association between hypoxia in the MDA-
MB-157 TNBC spheroids and upregulated activity of these stem 
cell markers.
Breast tumor cells with CD44high/CD24low surface markers 
expression were first proposed as breast CSCs with high 
tumorigenic capacity[65] and subsequently validated in other 
studies.[66–69] Nevertheless, growing evidence suggests 
heterogeneity in populations of CSCs and that breast CSCs 
cannot be stratified using this marker only.[70,71] Examining 
metastatic deposits of mammary tumors showed variable 
expression of CSC markers in different tumor samples and 
lack of CD44 expression in about one-third of tumor samples 
but expression of other CSC markers in these cells.[72] Ele-
vated levels of CD24 alone correlated with advanced disease 
stages in several types of human epithelial cancers including 
breast cancer and increasing tumor grade and malignancy.[73,74] 
Recent studies also show that hypoxia promotes CD24 expres-
sion[75,76] and that CD44−/CD24+ phenotype predicts poor out-
come.[67,77,78] Furthermore, expression of the transmembrane 
glycoprotein CD133 in primary breast tumors and breast cancer 
cell lines has been associated with self-renewal of cells,[79] tumor 
Adv. Healthcare Mater. 2016, 5, 2788–2798
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Figure 8. Dose–response of MDA-MB-157 spheroids made with 1.0 × 
105 and 1.5 × 104 cells to cisplatin treatment. Error bars represent the 
standard error of mean.
Figure 9. q-PCR analysis of expression of a) CD24, b) CD133, and c) Nanog in 1.5 × 104 and 1.0 × 105 cell density spheroids of MDA-MB-157 cells 
normalized against mRNA levels of a monolayer of cells. Expression levels are relative to β-actin and HPRT and calculated using the ΔΔCt method. 
Fold change in mRNA expression represent 2−ΔΔCt. Error bars represent the standard error of mean for three trials. Largest cryosections of 1.5 × 104 
and 1.0 × 105 cell density spheroids immunostained for cancer stem cell markers d) CD24 (green) and e) CD133 (red). Blue represents nuclei staining 
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size and grade,[80] tumor angiogenesis,[81,82] invasiveness,[83] and 
metastasis.[84] Targeting CD133 prevents local tumor recurrence 
in mouse models of breast cancer.[85,86] Therefore, expression 
of CD24 and CD133, but not CD44, in MDA-MB-157 tumor 
spheroids in our study is consistent with these findings and 
agrees with identified variability in CSC markers among dif-
ferent lines of breast cancer cells.[87] Expression of embryonic 
stem cell pluripotency markers Sox2, Oct4, and Nanog has also 
been reported in poorly differentiated breast cancer cells and 
associated with poor clinical outcome,[88–90] suggesting that reg-
ulatory networks controlling the function of stem cells may also 
be active in breast tumors. Recent studies show that hypoxia 
leads to transcriptional activation of the gene encoding Nanog 
in breast CSCs and Nanog-expressing cells present tumor ini-
tiation capacity in NSG mice.[6,91,92] Overall, this study suggests 
association of hypoxia and CSCs in TNBC spheroids and that 
the ATPS technology provides a useful tumor model for future 
studies of CSCs and heterogeneity of these cells in distinct 
environments.
3. Conclusions
The ATPS microprinting approach enabled convenient produc-
tion of spheroids of well-defined size in standard 384 microwell 
plates and drug treatment and downstream biochemical anal-
ysis of cellular responses in the same plate. Resulting spheroids 
reproduced key properties of solid tumors including compact 
morphology and deposition of major ECM proteins. Increase 
in cell density of spheroids resulted in a preferential cell pro-
liferation close to the periphery of spheroids and hypoxia in the 
core region, indicating consumption of extracellular oxygen by 
tightly packed layers of cells at the peripheral zone. Hypoxic 
spheroids showed resistance to a standard chemotherapy drug 
(doxorubicin) over a wide concentration range. Imaging of drug 
diffusion into spheroids eliminated widely proposed diffusion 
limitations as the cause of resistance and emphasized a major 
role for hypoxia. A combination treatment of hypoxic spheroids 
with doxorubicin and a hypoxia-activated prodrug (TH-302) 
significantly reduced drug resistance, suggesting a potential 
strategy against multidrug resistance in tumors. Hypoxia in 
tumor spheroids was accompanied by the expression of several 
genes associated with breast cancer stem cells. Altogether, these 
findings demonstrated the utility of aqueous two-phase tumor 
spheroids in cancer research to develop biomimetic tumor 
models that exhibit key biological and functional properties of 
solid tumors such as hypoxia and drug resistance, and present 
a tool to study cancer stem cells.
4. Experimental Section
ATPS Preparation: BioUltra PEG (Sigma), Mw: 35 000 Da, and DEX 
(Pharmacosmos), Mw: 500 000 Da, were used to form an ATPS due to 
their biocompatibility.[93] PEG and DEX were prepared in complete cell 
culture media at 5% (w/v) and 12.8% (w/v), respectively. The polymer 
solutions were vortexed and then kept in a 37 °C water bath for 1 h to 
ensure complete dissolution. The PEG phase solution was filtered with a 
0.2 μm filter to remove any impurities. Both polymer solutions were then 
stored at 4 °C until use.
Cell Culture: Prior to spheroid formation, MDA-MB-157 TNBC cells 
were grown in T175 flasks at 37 °C and 5% CO2 to a confluent monolayer. 
Cells were cultured in Dulbecco’s Modified Eagle Medium (Sigma) 
supplemented with 10% fetal bovine serum (Sigma), 1% glutamine (Life 
Technologies), and 1% antibiotic (Life Technologies). Once confluent, 
cells were rinsed with phosphate buffered saline (PBS) and dissociated 
by incubating with 5 mL of trypsin for ≈7 min. The cells were collected 
and neutralized with 10 mL of complete medium, and centrifuged down 
for 5 min at 1000 rpm. The supernatant was removed and the cells were 
resuspended in 1 mL of medium for counting with a hemocytometer.
Spheroid Formation Using ATPS: A 384 well plate (destination plate) 
for spheroid formation was prepared by adding 30 μL of the immersion 
PEG phase to each well. The DEX phase was mixed at an equal volume 
with the MDA-MB-157 cell suspension at a density of 3.0 × 104 or 
2.0 × 105 cells per 0.3 μL. The addition of the DEX phase solution to 
these cell suspensions diluted DEX concentration to 6.4% (w/v) and 
adjusted the cell densities to 1.5 × 104 and 1.0 × 105 cells per 0.3 μL. 
Each well from a column of a 384 well plate (source plate) was filled with 
≈20 μL of the aqueous DEX phase containing cells. A liquid handling 
robot (Bravo SRT, Agilent) was used to mix the content of the wells of 
the source plate and then aspirate 0.3 μL from each well.[94] Then the 
solution was dispensed as a single drop into each well of one column of 
the PEG phase-containing destination plate. This process was repeated 
for all columns of the destination plate, which was then placed in an 
incubator. Within 24 h of incubation, a single spheroid of MDA-MB-157 
cells formed in each well.
Evaluation of Viability of Spheroids: A standard cellular metabolic 
activity detection assay (PrestoBlue) was utilized to determine the 
viability of spheroids. Metabolically active and viable cells reduce the 
resazurin compound in PrestoBlue, producing fluorescence detectable 
with a standard plate reader. Since the PrestoBlue assay had only been 
optimized by the manufacturer for monolayer cultures, the required 
incubation time was adjusted for 3D spheroid cultures. This was 
determined by forming MDA-MB-157 spheroids of 1.5 × 104, 2.5 × 104, 
5.0 × 104, and 1.0 × 105 cell density, adding the PrestoBlue reagent at 
10% of total well volume, and measuring their fluorescent signal at 
different time points. The different cell density spheroids were generated 
using the ATPS approach with a cell culture media renewal at 24 h and 
maintaining cultures for an additional 24 h prior to viability evaluation. 
Based on this optimization study, an incubation period was selected 
that produced a significant difference in the fluorescent signal among 
different sizes of spheroids.
Histological Examination of Spheroids: To perform histological 
examination, a previously established spheroid cryosectioning protocol 
was adapted.[95] First, three-day old MDA-MB-157 spheroids were gently 
pipetted from wells into 200 μL microcentrifuge tubes. Supernatant 
media transferred with spheroids was removed from tubes. Spheroids 
were fixed with 100 μL of 4% formaldehyde for 10 min at room 
temperature. Following fixation, the spheroids were gently rinsed with 
100 μL of PBS three times for 5 min. Spheroids were then incubated 
with 100 μL of 30% (w/v) sucrose solution at 4 °C until they sank to 
the bottom of the microcentrifuge tubes. This ensured water removal 
from spheroids and prevented crystal formation upon freezing. Next, an 
equal volume (100 μL) of a tissue freezing medium (Triangle Biomedical 
Sciences) was added to each tube and incubated at 4 °C overnight. 
The next day, cryomolds were prepared by flash-freezing with dry ice 
a thin layer of the tissue freezing medium in biopsy-sized cryomolds. 
Spheroids were then pipetted from the microcentrifuge tubes and 
dispensed onto the layer of the tissue freezing medium in the cryomold. 
The frozen layer of the medium was slightly melted at room temperature 
prior to mixing with the newly added medium containing the spheroid 
sample. It was important in this process to avoid bubble formation in 
the medium that would cause hole formation when cryosectioning. Once 
the tissue embedding medium was homogenous, a fresh second layer 
was added to the mold to immerse the spheroid sample, which then was 
flash frozen on dry ice to form frozen molds. Frozen molds containing 
spheroid samples were stored at −80 °C until use. A cryostat was used 
to section the samples to 10 μm thick slices. The slices were transferred 
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onto Superfrost Plus microscopic slides (Fisher) upon sectioning. 
Sections were stained with H&E to examine spheroid morphology and 
immunostained following standard procedures for specific markers such 
as a cell proliferation protein marker (Ki-67, Cell Signaling), hypoxia 
(pimonidazole, HypoxyProbe), extracellular matrix proteins type I 
collagen (Abcam), laminin (Sigma), and fibronectin (Sigma), and cancer 
stem cell markers CD24 (Abcam) and CD133 (Novus Biologicals). 
Expression of these proteins was detected using a fluorescent secondary 
antibody, Cy3 conjugated goat anti-rabbit (Ki-67, hypoxia, ECM), FITC 
conjugated donkey anti-mouse (CD24), or Alexa Fluor 594 conjugated 
donkey anti-mouse (CD133), obtained from Jackson ImmunoResearch. 
Nuclei were stained with Hoechst (Life Technologies). Fluorescent 
images were captured using an inverted fluorescent microscope (Axio 
Observer, Zeiss) equipped with a high resolution camera (AxioCam 
MRm, Zeiss) or using a confocal microscope (Fluoview FV1000, 
Olympus). ImageJ (NIH) was used for image processing and analysis 
of Ki-67 expression in spheroid sections. Each spheroid section in 
captured images was manually divided into elliptical rings; starting 
from the border toward the center of each section, each ring was 10% 
smaller in diameter than its preceding one. The number and size of 
rings used for analysis was based on the size of spheroid sections. The 
total fluorescence of each ring was measured and normalized to its area 
using the integrated density and area measurements in ImageJ.
Preparation of Drug Compounds and Testing: A 50 × 10−3 m stock 
solution of doxorubicin (Sellekchem) was prepared in dimethyl 
sulfoxide (DMSO) and stored at −80 °C according to the manufacturer’s 
instructions. TH-302 (Santa Cruz Biotechnology) was dissolved in DMSO 
at a concentration of 44.5 × 10−3 m and stored at −20 °C according to 
the manufacturer’s instructions. The desired drug concentrations for 
experiments were prepared by serial dilution of each stock solution 
in the complete cell culture medium. Since the drug solutions were 
directly added to wells containing half of the desired total volume, drug 
concentrations were prepared at 2× the desired concentration (for single 
drug experiments) or 4× the desired concentration (for combination 
drug experiments). Cisplatin (Spectrum Chemicals) was dissolved in 
ultrapure sterile water at a stock concentration of 2 mg mL−1, which 
was then serially diluted to 2× working concentrations for the drug test 
against MDA-MB-157 TNBC spheroids.
After MDA-MB-157 spheroid formation in ATPS at 24 h of culture 
(day 1), 30 μL of cell culture medium was directly added to the wells 
already containing the PEG phase solution. This addition of the medium 
disrupted the initial concentrations of PEG and DEX, causing a single 
phase solution of medium with small residues of polymers. After 72 h of 
spheroid culture (day 3), 30 μL of medium was removed from each well 
using a multichannel pipette. Then, 30 μL of drug solutions at varying 
concentrations (prepared at 2× the desired concentrations) was added to 
wells for single drug testing with doxorubicin or cisplatin. For combination 
drug testing with doxorubicin and TH-302, 15 μL of each drug solution at 
varying concentrations (prepared at 4× the desired concentrations) was 
added to wells. Wells containing control (nontreated) spheroids received 
30 μL of fresh medium. Spheroids were incubated for 48 h, and their 
viability was evaluated using the PrestoBlue assay.
q-PCR Analysis with Spheroids: MDA-MB-157 cells cultured as a 
monolayer and spheroids of 1.5 × 104 and 1.0 × 105 cells were lysed on 
the third day of culture using a Total RNA Kit (TRK) lysis buffer (Omega 
Biotek) and homogenized by passing through homogenizer mini 
columns (Omega Biotek). Total RNA was isolated from the samples using 
an RNA isolation kit (Omega Biotek). DNA was removed using RNase-
free DNase (Omega Biotek). Purity and concentration of isolated RNA 
was assessed using optical density (OD) 260/280 spectrophotometry 
(Synergy H1M, Biotek instruments). cDNA was synthesized from 1 μg 
of total RNA using random hexamer primers (Roche). Real time q-PCR 
was performed in a LightCycler 480 instrument II using a SYBR Green 
Master Mix (Roche). Briefly, 50 ng of cDNA was combined with the 
primer and the SYBR green Master Mix to a final volume of 15 μL. The 
reactions were pre-incubated at 95 °C for 5 min followed by 45 cycles of 
amplification, i.e., at 95 °C for 10 s, at 60 °C for 10 s, and at 72 °C for 
10 s. Specific primer sequences for all the genes investigated are listed 
in Table SI-1 in the Supporting Information. Expression levels of mRNA 
for different gene markers of CSCs and hypoxia were calculated relative 
to β-actin and hypoxanthine phosphoribosyltransferase (HPRT) using 
the ΔΔCt method. The fold change in mRNA expression was determined 
according to the 2−ΔΔCt method. Statistical analysis was performed 
between the larger and smaller spheroid fold changes using a Student’s 
t-test in Microsoft Excel software.
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Supporting Information is available from the Wiley Online Library or 
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